Inovio developing vaccines to target coronavirus variants

FILE PHOTO: Vials labelled “COVID-19 Coronavirus Vaccine” are placed on dry ice in this illustration taken, December 5, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) – U.S. drug developer Inovio Pharmaceuticals Inc said on Monday it was developing next-generation COVID-19 vaccine candidates that could be tailored to the known and potentially the unknown SARS-CoV-2 variants.

Inovio began developing a COVID-19 vaccine last year, but is running behind rivals who have already introduced vaccines in the United States. A late-stage U.S. study of Inovio’s vaccine candidate is expected to start in the second quarter of 2021.

Source: Read Full Article

Related posts:
  1. Fund backed by 20 drugmakers raises $140 million to save antibiotic pipeline
  2. Pfizer study deals new blow to South Africa's vaccine hopes
  3. South Africa puts AstraZeneca vaccinations on hold over variant data
  4. Fauci says U.S. political divisions contributed to 500,000 dead from COVID-19
  5. Indonesia permits private COVID-19 vaccination scheme